Inhibikase Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

9 Months Ended

Sep. 30, 2024

Summary of Calculation of Basic and Diluted Net Loss Per Share applicable to Common Stockholders

The following table presents the calculation of basic and diluted net loss per share applicable to common stockholders. Basic net loss per share is calculated by dividing net loss attributable to common shareholders by the weighted-average number of shares outstanding during the period which includes Pre-Funded Warrants and shares held in abeyance from date of issuance.


	Three Months Ended September 30,						Nine Months Ended September 30,
	2024			2023			2024			2023
Numerator:
Net loss	$	(5,778,066	)	$	(4,595,199	)	$	(15,387,309	)	$	(14,850,943	)
Denominator:
Weighted-average number of common shares outstanding – basic and diluted		8,882,570			6,162,671			7,592,103			5,977,841
Net loss per share applicable to common stockholders – basic and diluted	$	(0.65	)	$	(0.75	)	$	(2.03	)	$	(2.48	)

Summary of Shares Excluded from Calculation of Diluted Net Loss per Share Applicable to Common Stockholders

The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock method, because their effect would have been anti-dilutive for the periods presented:


	Nine Months Ended September 30,
	2024		2023
Options to purchase shares of stock		1,140,280		835,913
Warrants to purchase shares of stock		7,738,040		3,080,090
Total		8,878,320		3,916,003